Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00035295|
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : April 18, 2017
A clinical study to determine the efficacy and safety of an Treatment of MK0869
in the treatment of depression.
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder||Drug: MK0869, aprepitant Drug: Comparator: placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||584 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Double-Blind, Multicenter, Placebo-and Active-Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder|
|Actual Study Start Date :||November 8, 2001|
|Actual Primary Completion Date :||December 5, 2003|
|Actual Study Completion Date :||December 5, 2003|
- HAMD-17 total score at week 8. Tolerability.
- CGI-I score at week 8, at least 50% reduction in the HAMD-17 total score, and Sheehan Disability Score at Week 8
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035295
|Study Director:||Medical Monitor||Merck Sharp & Dohme Corp.|